

VK-II-86

## Chemical Properties


CAS No. : 955371-84-3

Formula: C<sub>25</sub>H<sub>28</sub>N<sub>2</sub>O<sub>4</sub>

Molecular Weight: 420.5

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	VK-II-86 is a non- $\beta$ -blocking carvedilol analog. It prevents ouabain-induced cardiotoxicity
Targets(IC50)	Others, Adrenergic Receptor
In vivo	VK-II-86 are effective to prevent ouabain-induced apoptosis and spontaneous contractions indicative of arrhythmogenic activity without affecting inotropy and demonstrated to be effective in human models, thus emerging as a therapeutic tool for the prevention of digitalis-induced arrhythmias and cardiac toxicity[1].

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.3781 mL	11.8906 mL	23.7812 mL
5 mM	0.4756 mL	2.3781 mL	4.7562 mL
10 mM	0.2378 mL	1.1891 mL	2.3781 mL
50 mM	0.0476 mL	0.2378 mL	0.4756 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

## Reference

Gonano L A , Sepúlveda, Marisa, Morell M , et al. Non- $\beta$ -Blocking Carvedilol Analog, VK-II-86, Prevents Ouabain-Induced Cardiotoxicity[J]. Circulation Journal, 2018.

Chakraborty A D , Gonano L A , Munro M L , et al. Activation of RyR2 by class I kinase inhibitors[J]. British Journal of Pharmacology, 2019, 176.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481